BPC-157: What the Preclinical Research Actually Shows

Every compound in the PTW research library exists because published researchers have examined something specific about it. BPC-157 is studied for its proposed role in tissue-repair signaling — but unlike the GLP-1 class of compounds covered on this site, BPC-157 has never been evaluated by the FDA and has no approved pharmaceutical drug product anywhere in the world. This guide lays out what the published literature actually says, distinct from the marketing claims that circulate around this peptide.

What Is BPC-157?

BPC-157 — short for Body Protection Compound 157 — is a synthetic pentadecapeptide, a chain of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from, and modeled after, a fragment of a larger protective protein originally identified in human gastric juice — part of a physiological system researchers have studied for its role in protecting and maintaining the gastrointestinal lining under mechanical and chemical stress. In older pharmacology literature, the compound is sometimes designated PL 14736.

BPC-157 is not a growth hormone secretagogue and is mechanistically distinct from compounds studied for direct effects on muscle hypertrophy or fat metabolism. The published research instead centers on tissue-repair signaling — angiogenesis, growth-factor pathway modulation, and related processes examined primarily in animal models and cell-culture systems.

The regulatory picture is the most important thing to understand before reading further. Unlike semaglutide, tirzepatide, or retatrutide — all GLP-1-class compounds with either FDA approval or an active late-stage clinical trial program — BPC-157 has no FDA-approved drug product, no approved indication, and no completed Phase 3 human trial program anywhere in the world. It has occasionally been flagged in FDA communications regarding compounding-pharmacy practices, which is a separate regulatory question from drug approval. At Portal to Wellness, BPC-157 is sold exclusively as a Research Use Only (RUO) compound for laboratory research and in-vitro study by qualified researchers — not for human or animal consumption, injection, or any therapeutic application.

One frequently cited historical data point is a small Phase II trial referenced in the literature under the PL 14736 designation, examining the compound in an inflammatory bowel disease context. That trial is often mentioned in review articles as an early signal of human tolerability, but it has not been independently replicated, is not part of a completed registration-track clinical program, and does not substitute for the kind of structured, multi-phase human trial data available for FDA-approved compounds. Researchers should treat it as a single early data point rather than an established human evidence base.

Benefits: What Preclinical Research Has Examined

“Benefits” in the context of BPC-157 means findings reported in animal-model and in-vitro studies — not claims about outcomes in human users. The published literature has most consistently examined the following research models:

• Tendon repair models: Rat models of Achilles and patellar tendon injury have reported accelerated repair markers with BPC-157 administration, including improved collagen organization and earlier recovery of mechanical strength compared to untreated controls.
• Ligament repair models: Studies in medial collateral ligament injury models have reported similar findings — faster repair markers and reduced local inflammatory signaling at the injury site.
• Muscle repair models: Crush-injury and muscle-transection studies in animal models have reported accelerated regeneration of skeletal muscle tissue, with researchers noting evidence of satellite-cell activation consistent with a regenerative signaling role.
• Bone healing models: Fracture models in rodents have reported earlier bone-bridge formation and functional recovery markers in BPC-157-treated animals versus controls.
• Gastrointestinal models: The original and most extensive area of study — multiple GI-injury models (gastric ulcer, colitis, fistula) report protective and repair-promoting effects, consistent with the compound’s origin as a gastric-protein-derived fragment.
• Angiogenesis and vascular signaling: A substantial body of in-vitro and in-vivo work has examined BPC-157’s effect on VEGFR2-mediated blood-vessel formation, a mechanism researchers propose underlies many of the tissue-repair findings above.

A 2025 narrative review in Current Reviews in Musculoskeletal Medicine (McGuire et al.) summarizes this literature while explicitly flagging the gap between the animal-model evidence and what can currently be said about human outcomes — a caveat that applies across nearly every benefit category listed above.

It is also worth noting, for research-transparency purposes, that a substantial share of the published BPC-157 literature originates from a small number of research groups (most prominently a Croatian laboratory associated with the Sikiric name across dozens of papers). That concentration doesn’t invalidate the findings, but independent replication by unaffiliated labs remains thinner than researchers would want before treating any single mechanism as fully settled.

Amounts Used in the Published Studies

We’re asked frequently what amount of BPC-157 the research used. The honest answer is more useful than a number, so here it is plainly.

There is no established human dose

BPC-157 has never completed a human dose-ranging trial. There is no approved labelling, no regulatory-reviewed dosing schedule, and no consensus figure derived from controlled human research. Any specific human amount circulating online — on forums, vendor sites, or protocol charts — is extrapolation, not a finding. It did not come from a trial, because no such trial has reported one.

What the animal literature reports

The published work is overwhelmingly rodent research, and it reports amounts as micrograms or nanograms per kilogram of body weight — typically in the range of 10 µg/kg down to 10 ng/kg, administered intraperitoneally, intragastrically, or locally to the injury site depending on the model. Rat tendon, ligament, muscle-crush and gastrointestinal injury models dominate the literature.

Those figures cannot be converted into a human amount by simple arithmetic. Allometric scaling between species accounts for differences in metabolic rate and body surface area, but it is an estimate used to select a starting point for a first human trial — not a substitute for having run one. Route of administration matters as much as quantity: much of the BPC-157 literature used routes that have no equivalent in general use.

What this means in practice

• The evidence base is preclinical. Encouraging results in rodent injury models are a reason to study a compound further, not a demonstration that it works in humans at any amount.
• Purity determines whether any figure means anything. A stated milligram content is a claim until an independent laboratory measures it. See our lab testing status for where our own testing stands.
• Anyone presenting a confident BPC-157 protocol is not citing a trial, because there isn’t one to cite.

Reported here as a summary of published preclinical research. Not medical advice, not a dosing instruction, and not a description of use in humans. Portal to Wellness sells research-use-only material.

Side Effects: What the Safety Literature Actually Shows

This is the section where BPC-157’s evidence base diverges most sharply from FDA-approved compounds. A pharmaceutical drug’s safety profile comes from structured Phase 1–3 human trials, adverse-event reporting systems, and years of post-market surveillance. BPC-157 has none of that. What exists instead:

• Preclinical tolerability data: Animal studies across the tendon, ligament, muscle, bone, and GI models referenced above have generally not reported significant adverse events at the doses studied — but “no adverse events observed in a controlled animal study” is a different evidentiary standard than a completed human safety trial.
• Limited human data: A small pilot study published in 2025 (Lee & Burgess, Alternative Therapies in Health and Medicine) examined intravenous BPC-157 administration in a small human cohort and is one of the only published human-subject safety datasets available for this compound. It is a pilot-scale study, not a controlled trial designed to establish a safety profile, and its findings have not been independently replicated at scale.
• What is not known: There is no published data on long-term human exposure, no established human pharmacokinetic profile at scale, no systematic adverse-event reporting comparable to an FDA MedWatch dataset, and no completed dose-ranging human safety trial. Researchers should treat BPC-157’s human safety profile as an open question rather than a settled one.

This is exactly why BPC-157 is classified and sold strictly as a Research Use Only compound — the evidentiary basis for characterizing its effects and safety profile in humans simply does not yet exist in the published literature.

Mechanism of Action

The mechanisms below are proposed pathways studied in the published literature, not confirmed clinical mechanisms of action in the pharmaceutical-labeling sense. Research has converged on several interrelated signaling pathways:

Angiogenesis (VEGFR2 pathway)

Tissue repair requires blood supply. Researchers have reported that BPC-157 upregulates VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) expression, the primary receptor pathway driving new blood-vessel formation. Multiple tendon and wound-healing models have documented measurable neovascularization at the site of injury following BPC-157 administration, alongside downstream FAK-paxillin signaling implicated in endothelial cell migration.

Growth-factor pathway modulation

Fibroblast activity drives collagen synthesis in tendon and ligament repair. Studies report that BPC-157 increases fibroblast migration and proliferation in vitro, and modulates receptor expression for growth factors including EGF (Epidermal Growth Factor). Some research models also report upregulation of Growth Hormone receptor expression in tendon fibroblasts, a mechanism researchers propose may make treated tissue more responsive to endogenous GH signaling — distinct from any claim about exogenous GH administration.

Nitric oxide (NO) system modulation

BPC-157 has been studied for its interaction with the nitric oxide system, which regulates vascular tone and local inflammatory signaling. Researchers have proposed this pathway as a contributor to the compound’s studied gastroprotective and anti-inflammatory effects in animal models.

Egr-1 and Akt/PI3K signaling

Additional research has examined BPC-157’s effect on Egr-1 transcription-factor activity and Akt/PI3K survival signaling in endothelial cells — both implicated in the broader angiogenic and cell-survival pathways described above.

Taken together, the mechanistic literature is relatively well-characterized at the cellular and animal-model level. What remains unresolved is how directly these mechanisms translate into predictable, dose-dependent effects in human physiology — the step that would normally be established through the human clinical trial process BPC-157 has not undergone.

Comparison: BPC-157 vs. TB-500

BPC-157 and TB-500 (a synthetic fragment of thymosin beta-4) are the two most frequently co-studied peptides in the tissue-repair research category. They are often discussed together, but the published literature describes genuinely different proposed mechanisms.

Because the two proposed mechanisms are complementary rather than redundant — VEGFR2-driven local repair signaling versus actin-mediated systemic cell migration — researchers frequently reference them together in recovery-research literature and combination-research designs, often described informally as a “recovery stack.” Neither compound’s evidentiary basis is stronger than the other; both remain in the preclinical/early-research category, and human data for both is limited.

This comparison is covered in more depth, including the research rationale for studying the two peptides together, in our companion articles: BPC-157 and TB-500: Two Mechanisms Compared and BPC-157 vs TB-500: How They Differ in Tissue-Repair Research.

Frequently Asked Questions

What is BPC-157?
BPC-157 is a synthetic pentadecapeptide (15 amino acids) modeled on a fragment of a protective protein identified in human gastric juice. It is studied in animal models and in-vitro systems for its proposed role in tissue-repair signaling pathways, including angiogenesis and growth-factor modulation.

Is BPC-157 FDA-approved?
No. BPC-157 is not FDA-approved for any human or animal use and has no marketed pharmaceutical drug product. It has been referenced in past FDA communications concerning compounding-pharmacy practices, which is a separate matter from drug approval.

How does BPC-157’s evidence base compare to GLP-1 compounds like semaglutide or tirzepatide?
It is considerably earlier-stage. GLP-1 compounds have completed large Phase 3 human trial programs and, in several cases, FDA approval. BPC-157’s published evidence is overwhelmingly preclinical (animal-model and in-vitro), with only a small number of early-stage human studies and no completed large-scale human clinical trial program.

What has research examined regarding BPC-157 and tissue repair?
Preclinical studies in tendon, ligament, muscle, bone, and gastrointestinal injury models have reported findings consistent with accelerated repair markers, alongside in-vitro and in-vivo research on angiogenesis (VEGFR2 pathway) and growth-factor signaling proposed to underlie those findings.

What is known about BPC-157 safety in humans?
Very little, compared to an approved pharmaceutical. Most tolerability data comes from animal studies. A small 2025 pilot study is among the only published human-subject data available, and it does not constitute a controlled safety trial. No long-term human safety or pharmacokinetic data has been published.

How is BPC-157 sold at Portal to Wellness?
Strictly as a Research Use Only (RUO) compound intended for laboratory research and in-vitro study by qualified researchers — not for human or animal consumption, injection, diagnosis, treatment, or prevention of any condition.

Research Guides

Portal to Wellness does not publish dosing instructions, administration schedules, or treatment protocols for human or animal use, and nothing in this article should be read as one. For general information on how the published literature structures recovery-and-repair-category peptide research and where BPC-157 fits into the broader research landscape discussed on this site, see our Repair-Pathway Research Compounds.

Products

Research-grade BPC-157 is available at Portal to Wellness in the following options:

• BPC-157 500 mcg – 100 pcs per bottle (Research Use Only)
• BPC-157 + TB-500 Injectable – 10mg/vial (5mg BPC-157 + 5mg TB-500)
• BPC-157 500mcg + TB-500 500mcg Oral – 100 Capsules (Research Use Only)

Related research-grade compounds referenced in the Comparison section above are also available: TB-500 individually, and as part of the broader Repair-Pathway Research Set.

Sources: McGuire et al., “Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing,” Curr Rev Musculoskelet Med (2025) | Lee & Burgess, “Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study,” Altern Ther Health Med (2025) | Seiwerth et al., “Stable Gastric Pentadecapeptide BPC 157 and Wound Healing,” Front Pharmacol (2021) | Sikiric et al., “Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key… Angiogenesis and the NO-System,” Pharmaceuticals (2025) | Matek et al., “Tendon, Ligament, and Muscle Injury… Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157 — A Review,” Pharmaceuticals (2026) | Mateescu et al., “BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers,” Pharmaceutics (2026)

All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.

Looking for the product? See BPC-157 formats, specifications and pricing — injectable and oral, with current lab testing status stated plainly.